10X GENOMICS INC's ticker is TXG and the CUSIP is 88025U109. A total of 93 filers reported holding 10X GENOMICS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 1.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $31,972 | -54.4% | 775,086 | -38.3% | 0.12% | -50.4% |
| Q2 2023 | $70,153 | +19.7% | 1,256,326 | +19.6% | 0.24% | +14.2% |
| Q1 2023 | $58,585 | -98.7% | 1,050,089 | +1675.0% | 0.21% | +1666.7% |
| Q1 2022 | $4,500,000 | -64.7% | 59,159 | -30.9% | 0.01% | -58.6% |
| Q4 2021 | $12,757,000 | +78.0% | 85,642 | +73.9% | 0.03% | +70.6% |
| Q3 2021 | $7,168,000 | -11.5% | 49,239 | +19.1% | 0.02% | -15.0% |
| Q2 2021 | $8,097,000 | -87.6% | 41,348 | -88.6% | 0.02% | -88.0% |
| Q1 2021 | $65,549,000 | -19.9% | 362,146 | -37.4% | 0.17% | -22.7% |
| Q4 2020 | $81,877,000 | +32.2% | 578,226 | +16.4% | 0.22% | +9.1% |
| Q3 2020 | $61,941,000 | +31.3% | 496,805 | -5.9% | 0.20% | +20.0% |
| Q2 2020 | $47,165,000 | -4.1% | 528,103 | -33.1% | 0.16% | -24.3% |
| Q1 2020 | $49,176,000 | -1.4% | 789,091 | +20.7% | 0.22% | +31.3% |
| Q4 2019 | $49,855,000 | +34.9% | 653,835 | -10.8% | 0.17% | +31.7% |
| Q3 2019 | $36,949,000 | – | 733,124 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management II, LLC | 1,358,528 | $49,504,760 | 100.00% |
| Meritech Capital Associates V L.L.C. | 1,061,682 | $38,687,692 | 9.44% |
| Decheng Capital Management III (Cayman), LLC | 359,554 | $13,102,148 | 4.90% |
| Sands Capital Ventures, LLC | 481,770 | $17,556 | 4.81% |
| Whitford Management LLC | 58,310 | $2,124,803 | 2.88% |
| FINANCIAL CONSULATE, INC | 156,457 | $5,701,293 | 1.99% |
| SRS Investment Management, LLC | 3,005,427 | $109,517,760 | 1.98% |
| BRANDYWINE MANAGERS, LLC | 11,208 | $408,420 | 1.43% |
| ARK Investment Management | 4,316,567 | $157,295,701 | 1.36% |
| Nikko Asset Management Americas, Inc. | 2,177,988 | $79,365,883 | 1.14% |